GlassScriptPhysician profile
Bobbi G Brady
NPI 1295145100
$3,983.21
in general payments reported to CMS, 2019-2025
27 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $50.59 · 2021: $303 · 2022: $709 · 2023: $855 · 2024: $1,236 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.41 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $635.24 | 2022-2025 | Xeomin |
| Galderma Laboratories, L.P. | $576.22 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $373.56 | 2020-2025 | |
| Abbvie INC. | $274.66 | 2021-2025 | Skyrizi |
| Leo Pharma INC. | $252.58 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $232.91 | 2021-2024 | Blu-U |
| Genzyme Corporation | $232.35 | 2019-2025 | |
| Pfizer INC. | $209.33 | 2019-2025 | |
| Janssen Biotech, INC. | $195.27 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $161.77 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $105.84 | 2022-2025 | Sotyktu |
| Ucb, INC. | $97.14 | 2023-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $96.23 | 2021-2024 | Libtayo, Dupixent |
| Revance Therapeutics, INC. | $68.57 | 2024 | Daxxify |
| Dermavant Sciences, INC. | $67.66 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $52.43 | 2021-2025 | Ameluz |
| Kyowa Kirin, INC. | $47.04 | 2024-2025 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $46.58 | 2023 | Valchlor |
| Allergan, INC. | $45.00 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $44.73 | 2023-2025 | Zoryve |
| Amgen INC. | $43.85 | 2022-2023 | Otezla |
| Genentech USA, INC. | $28.51 | 2019-2021 | |
| Almirall LLC | $20.88 | 2024 | Seysara |
| Incyte Corporation | $20.57 | 2023 | Opzelura |
| Celgene Corporation | $20.08 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.30 | 2022 | |
| Convatec INC. | $14.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobbi Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.